BioSpace News Archive

OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2021 financial results after the close of the U.S. financial markets on Thursday, August 12, 2021.

A new peer-reviewed and published study is revealing a natural option for the millions of women and men who suffer from recurrent urinary tract infections (UTIs).

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced its participation in the Wedbush PacGrow Healthcare Virtual Conference.

Zynerba Pharmaceuticals, Inc. today announced that Company management will participate in a fireside chat during the Canaccord Genuity 41 st Annual Growth Conference being held virtually on Wednesday, August 11, 2021 at 1:30 p.m. ET.

Record Second-Quarter 2021 Net Sales of $832.5 Million Increased 80 Percent; Second-Quarter 2021 GAAP Net Income of $158.1 Million; Adjusted EBITDA of $366.9 Million.

Conference Call to be Held on Wednesday, August 11, 2021 at 5:00 p.m. (EDT)

Surmodics, Inc. , today announced results for its fiscal 2021 third quarter ended June 30, 2021 and updated its financial outlook for its fiscal 2021.

EDAP TMS SA, the global leader in robotic energy-based therapies, reports select preliminary unaudited second quarter financial and operating results.

Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced that Dr. Jeremy Bender, chief executive officer, is scheduled to participate in a panel discussion at the 12th Annual Wedbush PacGrow Healthcare Conference, which is being held virtually from August 10-11, 2021.

T-knife Therapeutics, Inc. a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for patients with solid tumors, today announced the appointment of cell therapy and immuno-oncology thought leader, Peggy Sotiropoulou, Ph.D., as its Chief Scientific Officer.